Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Shuttle Pharmaceuticals Holdings, Inc.

Get SEC filing alerts via email and in your feed for Shuttle Pharmaceuticals Holdings, Inc.

SHPH

Shuttle Pharmaceuticals Holdings, Inc.

About Shuttle Pharmaceuticals Holdings, Inc.

Shuttle Pharmaceuticals develops novel cancer therapies focused on enhancing radiation therapy. Its pipeline includes radiation sensitizers, HDAC inhibitors, and diagnostic biomarkers aimed at solid tumors like glioblastoma and prostate cancer. The company leverages proprietary platform technologies, collaborates with academic institutions, and seeks regulatory approvals to deliver safer, more effective cancer treatments with potential for personalized medicine applications.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Shuttle Pharmaceuticals Holdings, Inc.

1
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports Q1 2026 Financial Results with $2.2M Net Loss

Via official filing (AI summary) | 19 days ago | 0 comments

2
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports $11.7M Net Loss and Acquires Molecule.ai for $10.1M

Via official filing (AI summary) | 2 months ago | 0 comments

3
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports Q3 2025 Financial Results with Improved Net Loss

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports No Revenue, Increased Losses, and Significant Expense Growth in Latest 10-Q

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports $3.05 Million Net Loss and Increased R&D Expenses for Q1 2025

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports $9.1 Million Net Loss and Faces Nasdaq Compliance Challenges

Via official filing (AI summary) | over 1 year ago | 0 comments

7
1
Shuttle Pharmaceuticals Holdings, Inc. Shuttle Pharmaceuticals Reports Significant Financial Challenges, Net Loss Increases 111% in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments